Peregrine Pharma (PPHM) Misses Q3 EPS by 1c

Peregrine Pharma (NASDAQ: PPHM) reported Q3 EPS of ($0.04), $0.01 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $10.75 million versus the consensus estimate of $14 million.

GUIDANCE:

Peregrine Pharma sees FY2017 revenue of $60-65 million.

For earnings history and earnings-related data on Peregrine Pharma (PPHM) click here.

You May Also Be Interested In

• Gogoro Inc (GGR) Reports Q2 Loss of $0.24, Offers FY26 Revenue Guidance
• DA Davidson Reiterates Buy Rating on Jack Henry (JKHY)
• Howmet Aerospace Inc. (HWM) PT Raised to $328 at Bernstein SocGen Group